FDA’s Benefit/Risk Framework Will Focus On Communication, Not Quantification
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Director Woodcock tells BIO’s International Conference that the agency’s effort to formalize its approach to risk/benefit assessments will produce better sharing of approval conundrums, but not necessarily a mathematical solution to those problems.